NCT01904214View on ClinicalTrials.gov

A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Renal Impairment
Interventions
DRUG

BAF312

Treatment with a single oral dose of 0.25 mg BAF312

Trial Locations (2)

32809

Novartis Investigative Site, Orlando

Unknown

Novartis Investigative Site, Bucharest

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY